News

Galmed Signed Term Sheet for the Development of Novel Semaglutide Sublingual Formulation
Galmed Pharmaceuticals Ltd. (NASDAQ: GLMD) ("Galmed" or the "Company"), a clinical-stage biopharmaceutical company for cardiometabolic diseases and GI oncological indications announced today that it ...